The Industry

May 2010
Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p7
This section offers news briefs related to the pharmaceutical industry. GlaxoSmithKline signed a deal with Isis Pharmaceuticals, which is expected to increase its net up to 1.5 billion U.S. dollars. Galen Partners issued an investment to support Nautilus Neurosciences' launching of its first commercialized product, CAM-BIA. Fate Therapeutics plans to acquire Canadian biotech Verio Therapeutics.


Related Articles

  • Galen invests in pharma firm. Doran, Ryan // Fairfield County Business Journal;4/26/2010, Vol. 49 Issue 17, p7 

    The article reports that a 25 million dollars was invested by Galen Partners in Stamford to support the growth of Nautilus Neurosciences Inc.

  • Fate Therapeutics to acquire Verio Therapeutics.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p22 

    The article reports on the entry of U.S.-based stem cell therapeutics company Fate Therapeutics Inc. into a definitive agreement in acquiring Canadian biotechnology company Verio Therapeutics Inc.

  • Isis, Glaxo To Collaborate On GeneTrove. Webb, Marion // San Diego Business Journal;12/16/2002, Vol. 23 Issue 50, p8 

    Reports on the collaborative agreement between Isis Pharmaceuticals Inc. and GlaxoSmithKline PLC in California. Increase in the stock price of the biotechnology firm; Implementation of drug discovery programs; Stages of testing the safety and effectiveness of the drug in the treatment of lung...

  • Fate Steps in as Startup Buys Canadian Biotech. Chambers, Heather // San Diego Business Journal;5/3/2010, Vol. 31 Issue 18, p9 

    The article reports that Fate Therapeutics has agreed to purchase Canadian biotech Verio Therapeutics Inc. to enhance in the field of regenerative medicine.

  • Verio Puts its Global Destiny in the Hands of Fate (Therapeutics). Young, Donna // BioWorld Today;4/9/2010, Vol. 21 Issue 68, p1 

    The article reports on the agreement of Canadian regenerative medicine firm Verio Therapeutics Inc. to be acquired by Fate Therapeutics. Frank Gleeson, chief executive officer (CEO) of Verio, commends the deal by claiming that the firms have complimentary discovery and development platforms....

  • Depomed snaps up Nautilus migraine drug for $48.7M. Shaffer, Catherine // BioWorld Today;12/19/2013, Vol. 24 Issue 243, p1 

    The article reports on the acquisition of migraine drug, Cambia (diclofenac potassium for oral solution), of Nautilus Neurosciences Inc. by Depomed Inc. Jim Schoeneck, chief executive officer (CEO) of Depomed, discusses the details of the acquisition deal and its impact on the company's economic...

  • FINANCINGS.  // BioWorld Today;9/4/2013, Vol. 24 Issue 169, p7 

    The article reports on the initial public offering (IPO) of 4 million shares announced by biopharmaceutical company Fate Therapeutics Inc. in 2013.

  • Fate Tempts VCs With Stem Cell Business Model.  // Bioworld Week;12/10/2007, Vol. 15 Issue 50, p2 

    The article reports that Fate Therapeutics of Seattle, Washington, has raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. ARCH Venture Partners, Polaris Venture Partners and Venrock Associates were among the investors included in the round....

  • Juno Therapeutics. Investor's Business Daily // Investors Business Daily;5/7/2015, pA02 

    The article reports on the share purchase by Juno Therapeutics of Fate Therapeutics which is part of the deal to use the technology of Fate in modulating the T-cell product of Juno for cancer therapy and mentioned the increased shares of both company.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics